DEVELOPMENT PATHWAYS
Leveraging novel assets and potentially proprietary drug delivery platform(s) to provide a customized and targeted therapy with applications in oncology and other therapeutic areas.
In order to address the shift from "volume to value" based medicine in global markets to address unmet needs, Xennials Therapeutics Inc. has developed unique Target Product Profiles (TPPs) for novel oncology products. Our TPPs aim to potentially improve:
- Delivery to targeted cells
- Efficacy
- Safety and tolerability
- Toxicity profile
- Route of delivery
- Patient compliance
- Patient Quality of life (QOL)
- Physician quality of care
With the intention to improve treatment outcomes and reduce costs.
Xennials Therapeutics Inc. will lead full Clinical and Regulatory development of the following assets:
XNTR-956: Dimerization inhibitor of Signal Transducer and Activator of Transcription (STAT).
XNTR-955: Targeted multi inhibitor of STAT and Androgen Receptor (AR) N Terminal Domain (NTD).
XNTR-934: A construct comprised of the inhibitor of Program Cell Death Pathway (PD-1) and Targeted dual inhibitor of STAT and AR NTD.
XNTR-936: A construct comprised of the targeted dual inhibitor of STAT and AR NTD and Poly ADP Ribose Polymerase (PARP) inhibitor.
XNTR-924: A construct comprised of the targeted dual inhibitor of STAT and AR NTD and Epidermal Growth Factor Receptor (EGFR) targeting moiety.
XNTR-938: A construct comprised of dimerization inhibitor of STAT and EGFR inhibitor targeting moiety.